Cannabinoids for the treatment of rheumatic diseases — where do we stand?

Daphna Katz-Talmor, Itay Katz, Bat Sheva Porat-Katz, Yehuda Shoenfeld

Research output: Contribution to journalReview articlepeer-review

Abstract

As medical use of cannabis is increasingly legalized worldwide, a better understanding of the medical and hazardous effects of this drug is imperative. The pain associated with rheumatic diseases is considered a prevalent indication for medicinal cannabis in various countries. Thus far, preliminary clinical trials have explored the effects of cannabis on rheumatoid arthritis, osteoarthritis and fibromyalgia; preliminary evidence has also found an association between the cannabinoid system and other rheumatic conditions, including systemic sclerosis and juvenile idiopathic arthritis. The potential medicinal effects of cannabis could be attributable to its influence on the immune system, as it exerts an immunomodulatory effect on various immune cells, including T cells, B cells and macrophages. However, the available evidence is not yet sufficient to support the recommendation of cannabinoid treatment for rheumatic diseases.

Original languageEnglish
Pages (from-to)488-498
Number of pages11
JournalNature reviews. Rheumatology
Volume14
Issue number8
DOIs
StatePublished - 1 Aug 2018

Fingerprint

Dive into the research topics of 'Cannabinoids for the treatment of rheumatic diseases — where do we stand?'. Together they form a unique fingerprint.

Cite this